We are a global specialty pharmaceutical group focused on developing and commercialising treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for the general population.

What is a Stroke?

Annual Report 2023

On 29 August 2023 CLINUVEL announced its latest Annual Report, delivering on its long-term strategy.

Access the Annual Report 2023 microsite

Confirming the potential of our products
to repair UV-induced DNA damage

Evaluating afamelanotide
as treatment for AIS

Pioneering the concept of
medicinal photoprotection

We aim to grow our knowhow continuously
and establish a learned community

doses of SCENESSE® administered
>1,400 individuals have received SCENESSE®

Pharmaceutical Technology

CLINUVEL is developing novel pharmaceuticals with known photoprotective, antioxidative, anti-inflammatory, vasoactive and anti-oncotic properties. Read more.

A naturally occurring peptide hormone which is released by skin cells in response to the stimulation by ultraviolet radiation (UVR). Afamelanotide is a synthetic analogue of α-MSH. Click here to read more. 

Read more about SCENESSE® (afamelanotide 16mg) CLINUVEL’s proprietary first-in-class-drug.


Light and the

CLINUVEL is a leader in the field of photomedicine, investigating the interaction of light and human biology and pioneering the concept of medicinal photoprotection – protecting skin from light. The concentration of resources and efforts on photomedicine has made CLINUVEL a leader in the field.

DNA Repair

DNA Repair Program:
Xeroderma Pigmentosum

XP patients exhibit extreme deficiency in repair of UV-provoked damage to the DNA helix within the nucleus of skin cells. If left unrepaired, damaged DNA replicates and significantly increases the risk of skin cancers, including melanoma, in these patients.

Media Coverage

Media coverage on third-party sites can be found at the links below (please note that subscriptions may be required):


Get in touch.